全文获取类型
收费全文 | 71543篇 |
免费 | 5616篇 |
国内免费 | 1664篇 |
专业分类
耳鼻咽喉 | 1072篇 |
儿科学 | 1368篇 |
妇产科学 | 1770篇 |
基础医学 | 9145篇 |
口腔科学 | 1214篇 |
临床医学 | 7015篇 |
内科学 | 10907篇 |
皮肤病学 | 558篇 |
神经病学 | 4758篇 |
特种医学 | 2349篇 |
外国民族医学 | 11篇 |
外科学 | 5430篇 |
综合类 | 9306篇 |
一般理论 | 1篇 |
预防医学 | 8724篇 |
眼科学 | 749篇 |
药学 | 7904篇 |
109篇 | |
中国医学 | 2581篇 |
肿瘤学 | 3852篇 |
出版年
2023年 | 1109篇 |
2022年 | 1625篇 |
2021年 | 2831篇 |
2020年 | 2887篇 |
2019年 | 2318篇 |
2018年 | 2345篇 |
2017年 | 2444篇 |
2016年 | 2415篇 |
2015年 | 2505篇 |
2014年 | 4646篇 |
2013年 | 5375篇 |
2012年 | 4228篇 |
2011年 | 4605篇 |
2010年 | 3472篇 |
2009年 | 3410篇 |
2008年 | 3328篇 |
2007年 | 3296篇 |
2006年 | 2844篇 |
2005年 | 2472篇 |
2004年 | 2167篇 |
2003年 | 1824篇 |
2002年 | 1596篇 |
2001年 | 1371篇 |
2000年 | 1179篇 |
1999年 | 1097篇 |
1998年 | 866篇 |
1997年 | 855篇 |
1996年 | 792篇 |
1995年 | 790篇 |
1994年 | 753篇 |
1993年 | 592篇 |
1992年 | 611篇 |
1991年 | 593篇 |
1990年 | 467篇 |
1989年 | 460篇 |
1988年 | 410篇 |
1987年 | 356篇 |
1986年 | 355篇 |
1985年 | 487篇 |
1984年 | 448篇 |
1983年 | 284篇 |
1982年 | 378篇 |
1981年 | 300篇 |
1980年 | 271篇 |
1979年 | 262篇 |
1978年 | 173篇 |
1977年 | 156篇 |
1976年 | 153篇 |
1975年 | 127篇 |
1974年 | 89篇 |
排序方式: 共有10000条查询结果,搜索用时 18 毫秒
1.
《Clinical lung cancer》2022,23(3):191-194
BackgroundTo accelerate drug approvals while maintaining scientific rigor in the evaluation of a therapeutic's efficacy and safety, the United States Food and Drug Administration now considers real-world data (RWD) to support New Drug Applications and expanded indications. Response Evaluation Criteria in Solid Tumors (RECIST) are the gold standard in clinical trials, but the derivation of RECIST-based treatment response from RWD is unproven. This study investigated the feasibility of implementing RECIST criteria in RWD by comparing lung cancer response assessments from RECIST-based measurement of lesions on archived radiologic films with results from medical oncologist and radiologist narratives recorded in electronic health records (EHR).Materials and MethodsResponse to index treatment via different assessment approaches was compared among 30 metastatic non-small cell lung cancer (mNSCLC) patients receiving systemic treatment (index) after progression on a platinum or anti-PD(L)-1-containing regimen. Specifically, responses based on assessments documented in the medical oncologists’ narratives were compared to a radiologist's assessments of archived images using RECIST v1.1 criteria. Each patient's best overall response was characterized as complete or partial (CR/PR), stable disease (SD), progressive disease (PD), or not evaluable (NE).ResultsSimilar distributions of best overall response and substantial concordance (77%) between medical oncologist-reported and radiologist re-assessed responses were observed. There were no instances of CR/PR to PD or PD to CR/PR discordance.ConclusionsResults suggest that accurate treatment responses, similar to RECIST, may be derived using RWD. Further validation and improvement of real-world response assessment are needed to develop a scalable real-world approach for response assessment. 相似文献
2.
《Transfusion Clinique et Biologique》2022,29(3):269-272
A delayed haemolytic transfusion reaction (DHTR) encompasses a positive direct antiglobulin test (DAT) developed anytime between 24 hours to 28 days after cessation of transfusion, a positive eluate or a newly identified alloantibody in the plasma or serum along with features of haemolysis in the patient. Routinely, it is expected that with the transfusion of one unit of packed red cells in a patient of average height and weight, the haemoglobin level and hematocrit increase by 1 g/dL and 3% respectively. However, in a patient with DHTR, an inadequate rise of post-transfusion haemoglobin (< 1 g/dL) or rapid fall in haemoglobin back to pre-transfusion levels is observed. Kidd antibodies are particularly known to cause DHTR, maybe alone or in unison with other antibodies. Detection of these alloantibodies is consequential in providing good transfusion support to these patients. These events may be difficult to detect as they may present as varied clinical features or immunological nuisances. In this case series, we have presented three cases of DHTR with special emphasis on their clinical presentations, immunohaematological evaluations, laboratory parameters and the role of proper transfusion support in these patients to avoid further complications. 相似文献
3.
4.
《Vaccine》2022,40(18):2525-2527
5.
《Vaccine》2022,40(30):4038-4045
PurposeAs protection from COVID-19 following two doses of the BNT162b2 vaccine showed a time dependent waning, a third (booster) dose was administrated. This study aims to compare the antibody response following the third dose versus the second and to evaluate post-booster seroconversion.MethodsA prospective observational study conducted in Maccabi Healthcare Services. Serial SARS-CoV-2 Spike IgG tests, 1,2,3 and 6 months following the second vaccine dose and one month following the third were obtained. Neutralizing antibody levels were measured in a subset of participants. Per individual SARS-CoV-2 Spike IgG titer ratios were calculated one month after the booster administration compared to titers one month following the second dose and prior to booster.ResultsAmong 110 participants, 56 (51%) were women. Mean age was 61.7 ± 1.9 years and 66 (60%) were immunocompromised. One month after third dose, IgG titers were induced 7.83 (95 %CI 5.25–11.67) folds and 2.40 (95 %CI 1.90–3.03) folds compared to one month after the second, in the immunocompromised and immunocompetent groups, respectively. Of the 17 immunocompromised participants who were seronegative after the second dose, 4 (24%) became seropositive following the third. Comparing the titers prior to the third dose, an increase of 50.7 (95 %CI 32.5–79.1) fold in the immunocompromised group and 25.7 (95 %CI 19.1–34.7) fold in and immunocompetent group, was observed.ConclusionA third BNT162b2 vaccine elicited robust humoral response, superior to the response observed following the second, among immunocompetent and immunocompromised individuals. 相似文献
6.
7.
8.
9.
AimTo examine the effectiveness of a Humanoid Diagram Teaching Strategy (HDTS) on care capabilities and retention of novice nurses.BackgroundGuiding novice nurses in clinical practice is a matter of concern and the use of diagrams in assisting the learning process and to promote learning efficiency has been acknowledged.DesignThis is a quasi-experimental study with asynchronous repeated measurements for the experimental and control groups.MethodsThe study was conducted in a medical centre in southern Taiwan with 24 novice nurses. The intervention, Humanoid Diagrams Teaching Strategy, contained three parts: the head and neck; trunk; and limbs. The HDTS was applied three time weekly. Each session lasted approximately 30 min and the training lasted 4 weeks. The effectiveness of HDTS was measured using Mini-CEX, CbD and retention rates in the 3rd and 6th months of novice nurses’ experience.ResultsAfter the HDTS, although increases in mini-CEX and CbD scores in the experimental group were greater than the control group, these differences were not statistically significant after considering the time interaction. But the 3rd month and 6th month novice nurses’ retention rates were statistically significantly different by comparing the differences under the time interaction effects in both groups.ConclusionsThe Humanoid Diagram Teaching Strategy is an effective tool for preceptors to use in assisting novice nurses in learning, improving their nursing care knowledge and technical skills and to increase their retention rate. 相似文献
10.
《Clinical oncology (Royal College of Radiologists (Great Britain))》2022,34(5):340-349
Following adoption of moderately hypofractionated radiotherapy as a standard for localised prostate cancer, ultrahypofractioned radiotherapy delivered in five to seven fractions is rapidly being embraced by clinical practice and international guidelines. However, the question remains: how low can we go? Can radiotherapy for prostate cancer be delivered in fewer than five fractions? The current review summarises the evidence that radiotherapy for localised prostate cancer can be safely and effectively delivered in fewer than five fractions using high dose rate brachytherapy or stereotactic body radiotherapy. We also discuss important lessons learned from the single-fraction high dose rate brachytherapy experience. 相似文献